tetano
Editor, Senior Moderator
Vaccine. 2018 Mar 1. pii: S0264-410X(18)30248-2. doi: 10.1016/j.vaccine.2018.02.061. [Epub ahead of print]
[h=1]H5N2 vaccine viruses on Russian and US live attenuated influenza virus backbones demonstrate similar infectivity, immunogenicity and protection in ferrets.[/h] Czak? R[SUP]1[/SUP], Vogel L[SUP]1[/SUP], Sutton T[SUP]1[/SUP], Matsuoka Y[SUP]1[/SUP], Krammer F[SUP]2[/SUP], Chen Z[SUP]3[/SUP], Jin H[SUP]3[/SUP], Subbarao K[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The continued detection of zoonotic influenza infections, most notably due to the avian influenza A H5N1 and H7N9 subtypes, underscores the need for pandemic preparedness. Decades of experience with live attenuated influenza vaccines (LAIVs) for the control of seasonal influenza support the safety and effectiveness of this vaccine platform. All LAIV candidates are derived from one of two licensed master donor viruses (MDVs), cold-adapted (ca) A/Ann Arbor/6/60 or ca A/Leningrad/134/17/57. A number of LAIV candidates targeting avian H5 influenza viruses derived with each MDV have been evaluated in humans, but have differed in their infectivity and immunogenicity. To understand these differences, we generated four H5N2 candidate pandemic LAIVs (pLAIVs) derived from either MDV and compared their biological characteristics in vitro and in vivo. We demonstrate that all candidate pLAIVs, regardless of gene constellation and derivation, were comparable with respect to infectivity, immunogenicity, and protection from challenge in the ferret model of influenza. These observations suggest that differences in clinical performance of H5 pLAIVs may be due to factors other than inherent biological properties of the two MDVs.
[h=4]KEYWORDS:[/h] Ann Arbor; Avian influenza; LAIV; Leningrad; Pandemic
PMID: 29503113 DOI: 10.1016/j.vaccine.2018.02.061
[h=1]H5N2 vaccine viruses on Russian and US live attenuated influenza virus backbones demonstrate similar infectivity, immunogenicity and protection in ferrets.[/h] Czak? R[SUP]1[/SUP], Vogel L[SUP]1[/SUP], Sutton T[SUP]1[/SUP], Matsuoka Y[SUP]1[/SUP], Krammer F[SUP]2[/SUP], Chen Z[SUP]3[/SUP], Jin H[SUP]3[/SUP], Subbarao K[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The continued detection of zoonotic influenza infections, most notably due to the avian influenza A H5N1 and H7N9 subtypes, underscores the need for pandemic preparedness. Decades of experience with live attenuated influenza vaccines (LAIVs) for the control of seasonal influenza support the safety and effectiveness of this vaccine platform. All LAIV candidates are derived from one of two licensed master donor viruses (MDVs), cold-adapted (ca) A/Ann Arbor/6/60 or ca A/Leningrad/134/17/57. A number of LAIV candidates targeting avian H5 influenza viruses derived with each MDV have been evaluated in humans, but have differed in their infectivity and immunogenicity. To understand these differences, we generated four H5N2 candidate pandemic LAIVs (pLAIVs) derived from either MDV and compared their biological characteristics in vitro and in vivo. We demonstrate that all candidate pLAIVs, regardless of gene constellation and derivation, were comparable with respect to infectivity, immunogenicity, and protection from challenge in the ferret model of influenza. These observations suggest that differences in clinical performance of H5 pLAIVs may be due to factors other than inherent biological properties of the two MDVs.
[h=4]KEYWORDS:[/h] Ann Arbor; Avian influenza; LAIV; Leningrad; Pandemic
PMID: 29503113 DOI: 10.1016/j.vaccine.2018.02.061